Causes of Addiction: Genetic, Developmental, and Environmental Risk Factors

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

The causes of addiction emerge from a changing interaction among inherited liability, development, exposure to psychoactive substances, learning, mental health, relationships, and social conditions. No single gene, childhood event, personality trait, or social circumstance determines whether a person develops a substance use disorder. Risk increases or decreases as these influences combine across the life course, and the pathways differ for alcohol, opioids, tobacco, cannabis, stimulants, and other drugs. Understanding causation therefore requires examining who is exposed, what makes repeated use more likely, why use becomes difficult to control in some people, and which circumstances support protection or recovery. The National Institutes of Health describes addiction vulnerability as a joint product of biological and environmental factors, while large genomic research demonstrates that liability includes both cross-substance and substance-specific components.

What Does It Mean to Ask What Causes Addiction?

An explanation of addiction must distinguish a cause of starting to use a substance from a cause of escalating use, developing clinically significant impairment, experiencing an overdose, or returning to use after treatment. These outcomes are related, but they are not interchangeable. Someone may drink alcohol without developing alcohol use disorder; someone may develop opioid use disorder following exposure through several different routes; and a person receiving an appropriately prescribed medication may develop physical dependence without displaying the impaired control and harmful pattern characteristic of addiction.

In clinical terminology, substance use describes exposure or consumption; risky use describes a pattern that raises the probability of harm; substance misuse is a variable public-health or everyday term whose meaning depends on context; and substance use disorder refers to a diagnosed pattern meeting established criteria. Addiction generally refers to the clinically significant, often compulsive end of the spectrum of substance-related disorders. Tolerance, meaning a reduced response after repeated exposure, and withdrawal, meaning symptoms after reduction or discontinuation, can occur through physiological adaptation. Neither phenomenon by itself establishes a substance use disorder. For the clinical framework and treatment distinctions, the central research chapter situates these concepts within diagnosis and care.

Exposure, initiation, escalation, and disorder are different causal stages

Substance access and exposure are prerequisites for substance-specific use, so family, prescribing practices, marketing, legal supply, peer networks, and local drug markets matter greatly at initiation. Among people who have used a substance, vulnerability to escalation may depend more strongly on pharmacology, inherited variation, repeated reinforcement, co-occurring symptoms, and the environment in which use occurs. The same factor may act differently at each stage. A young person's friends can influence first experimentation, while later severe disorder may persist through conditioned craving and withdrawal even after the peer environment changes. Twin research has found different relative genetic and shared-environment contributions to initiation versus problem use, supporting this stage-specific account. Rhee et al.

A risk factor is a characteristic or exposure associated with a higher probability of an outcome. A protective factor is associated with lower risk or greater resilience. Neither term automatically proves direct causation. Genetic inheritance, neighborhood selection, family background, previous behavior, and measurement limitations can confound observed associations. For example, an association between early experimentation and later disorder is important for prevention, but by itself cannot show that every additional early exposure independently causes later addiction. Strong causal inference asks whether the temporal order is established, whether alternative explanations were considered, and whether changing the exposure changes outcomes.

Genetic Contributions to Addiction Risk

Heritability is a population statistic, not an individual's destiny

Family, adoption, and twin studies consistently show that genetic differences contribute to variation in substance use disorders. Common estimates across substance classes are often roughly 40–60% in studied populations, although estimates depend on age, substance, phenotype, sample and environment. Heritability measures the share of variation between people attributable to genetic differences under the conditions of a particular study. It does not mean that 50% of any individual's addiction was caused by DNA, and it does not fix the probability of developing addiction. Changing exposure, access, social norms, and treatment can change outcomes even when inherited liability remains the same. NIH: Substance Use Disorders; Meyers and Dick.

The heritability of starting to use alcohol or tobacco may differ from the heritability of progression to problematic use. Family resemblance can also reflect shared environment, genetic-environmental correlation, and assortative mating. Twin models estimate contributions under statistical assumptions rather than directly reading genes. Large-scale genomic studies complement these designs by identifying common genetic markers, but the markers usually explain only a fraction of total estimated heritability. These approaches answer related, distinct questions.

Polygenic liability and shared vulnerability across substances

Addiction risk is highly polygenic: many genetic variants have individually small associations, and the combined influences span neural signaling, metabolism, behavioral regulation, stress response, and other pathways. A multivariate genome-wide association meta-analysis published in Nature Mental Health examined problematic alcohol use, problematic tobacco use, cannabis use disorder, and opioid use disorder, including more than one million participants of European ancestry and over 90,000 participants of African ancestry. The researchers identified 19 independent genome-wide significant variants for a common addiction-risk factor alongside substance-specific loci. The results support both shared liability and important differences among drug classes. The association of a particular locus with a statistical factor is not proof of a simple one-gene mechanism. Hatoum et al., 2023.

A shared liability may overlap with dimensions of externalizing behavior, impulsivity, psychiatric symptoms, and general vulnerability to substance-related problems. This overlap helps explain why disorders involving different drugs can cluster within individuals and families. Yet general predisposition and specific pharmacology remain relevant together: a variant influencing alcohol metabolism may act differently from one associated with broadly distributed behavioral tendencies. Population ancestry, genetic architecture, phenotype definitions, and available samples shape which signals researchers detect.

Genetic influences on drug effects and metabolism

Substances have distinct receptor targets, metabolic pathways, and reinforcement profiles. Variants that affect how rapidly alcohol is metabolized, for instance, can alter unpleasant physiological reactions and thereby influence alcohol-use risk. Other associations concern nicotine receptor biology or broader liability rather than a directly observed metabolic response. The existence of a biological association does not establish that genetic testing can identify which individual will develop a disorder or determine a treatment plan. The clinically meaningful question is how genetic variation combines with actual exposure, symptoms, medical history, and circumstances.

Family history is useful information, but it is not a diagnosis

A family history of alcohol or other substance use disorders is an important reason to discuss risk openly with a clinician. It can reflect inherited susceptibility, modeling, exposure, stressful family conditions, and unequal access to care. It neither establishes that a child will develop addiction nor implies that a family member caused another person's disorder. Conversely, the absence of diagnosed addiction in relatives does not rule out risk. Family history may be incomplete because of stigma, limited contact, diagnostic changes, or deaths before formal assessment.

Why polygenic scores are not clinical addiction tests

A polygenic score combines statistical associations across many common variants. Research scores may help investigate group-level mechanisms, but present performance, portability, fairness, and interpretation limit individual clinical usefulness. Scores derived largely from one ancestral population can perform differently in other populations. Predictive associations may partly capture social and environmental correlations; they can also be sensitive to the exact phenotype used in a study. Clinical decisions about screening, diagnosis, and treatment should therefore be based on validated assessment and the person's current needs rather than a consumer genetic-risk score. A 2024 clinical review of polygenic scores for substance use disorders describes these limitations and the work required before responsible clinical implementation.

Developmental Risk Across the Life Course

Childhood experiences establish patterns of opportunity and protection

Early childhood shapes emotion regulation, learning, relationships, behavioral self-control, exposure opportunities, and access to dependable support. Children who experience safe, responsive caregiving, predictable routines, supportive schools, and opportunities for positive social participation generally have more protective resources. Chronic adversity can increase vulnerability through multiple pathways, including stress burden, disrupted education, changes in supervision, and exposure to adult or peer substance use. These pathways overlap with genetic influences and structural disadvantages; they are rarely captured by a single questionnaire. NIDA's prevention principles and the NIH developmental research priorities support viewing protection as an ecological, developmental process.

Adverse childhood experiences include certain forms of abuse, neglect, household dysfunction, and exposure to violence or severe adversity. Studies commonly find dose-related associations between cumulative adversity and later substance-related outcomes. A 2024 systematic review of longitudinal evidence on adverse childhood experiences and adult cannabis outcomes identified 28 manuscripts, many from the United States. It found consistent associations, notably for childhood sexual abuse, while emphasizing variation in exposure and outcome measurement that constrains causal interpretation. Adverse childhood experiences as precursors to cannabis use in adulthood. Experiences of adversity should prompt assessment of support and safety, never assumptions that addiction is inevitable.

Adolescence is a period of changing reward, control, and social motivation

Adolescence involves extensive changes in social learning, motivational systems, executive functions, and sensitivity to peers. Brain development continues into young adulthood, but individuals mature at different rates and no single biological birthday determines judgment or vulnerability. Exploration and heightened attention to social rewards are normal features of development. When alcohol, nicotine, cannabis, or other substances become available during this period, repeated exposure can intersect with an evolving capacity to regulate behavior and predict consequences. The NIH youth substance-use resource identifies early use, stressors, relationships, and family background among interacting risk factors.

Early initiation consistently predicts later substance-related problems in many cohorts, partly because it may lengthen exposure and partly because it identifies young people already facing elevated risk. It is difficult to distinguish these mechanisms from inherited predispositions, externalizing traits, family instability, and peer environments through simple observational comparisons. Clinicians and educators can act on the association without claiming that every observed trajectory follows one mechanism. A young person who begins using early deserves support attentive to safety, frequency, harms, motivation, and developmental context, rather than an automatic diagnostic label.

Emerging adulthood changes access and opportunity

Leaving home, entering work or higher education, changing peer groups, new financial autonomy, and legal access to some substances alter the environment of use. For some people, increased structure and responsibility reduce consumption; for others, availability, unstable housing, stress, or irregular schedules increase risk. The relevance of risk factors shifts across development. A longitudinal social-determinants review found that family and school conditions influence initiation, peer and neighborhood conditions influence escalation, and employment, housing, justice-system involvement, and social support influence treatment and recovery trajectories. Lin et al., 2024.

Adult transitions and aging remain causally important

Addiction can develop or recur in adulthood. Injury, pain, bereavement, occupational changes, social isolation, psychiatric illness, caregiving demands, and exposure to medications or substances can change vulnerability. Later-life changes in metabolism, cognition, mobility, prescribing and medical illness affect the consequences of use. Older people may have symptoms mistakenly attributed to aging or another medical condition. Developmental risk is therefore a lifelong framework, not an explanation confined to adolescence.

Environment, Relationships, and Social Determinants

Availability and exposure are proximal determinants

A person cannot develop a substance-specific disorder without exposure to that substance. Availability depends on price, supply, prescribing systems, alcohol and tobacco retail practices, commercial promotion, cultural norms, peer access, and illicit markets. These influences matter at both individual and population scales. Policies that change access can shift initiation and consumption distributions, but their effects vary by substance, implementation, substitution opportunities, and enforcement. The scientific question involves which intervention changes harmful outcomes and for whom, rather than assuming that restricting a single route of supply resolves every risk. NIDA prevention framework.

Substance potency and contamination also shape outcomes after exposure. Overdose risk reflects drug class, combined substances, uncertain content, individual tolerance, route, and the immediate circumstances of use. Overdose is an acute toxic event and is not itself evidence that a person has a chronic substance use disorder. Conversely, a person can die from accidental opioid exposure without prior addiction. This distinction helps prevent conflating toxicology, drug-market conditions, and psychiatric diagnosis.

Peers contribute through influence and selection

Friends and social networks affect attitudes, perceived norms, opportunities, and what behaviors seem rewarding or acceptable. At the same time, people select friends partly on the basis of existing preferences and behavior. A systematic review of longitudinal studies of adolescent alcohol use found repeated prospective associations between affiliation with drinking peers and subsequent alcohol use; it also cautioned that estimating the separate contributions of peer influence and peer selection remains difficult. Peer influence and selection systematic review. Prevention that supports constructive friendships and alternative social rewards may address both exposure and belonging.

Family relationships and intergenerational patterns

Parental substance-related problems can coincide with genetic liability, modeling of use, inconsistent caregiving, economic strain, or adverse experiences. These mechanisms require careful separation. Many families provide strong protection despite a history of addiction, and many people develop substance use disorders without such a history. Family participation can improve access to care, communication, monitoring, and practical support when it is safe and welcome. Family histories of adversity belong within a wider account of developmental experience; the related article Growing Up With Parental Substance Use: Childhood Adversity and Adult Outcomes examines those outcomes in detail.

Poverty, housing, discrimination, and access to care

Structural and socioeconomic conditions influence exposure, stress, opportunity, health care access, and survival following harm. Poverty does not characterize everyone who develops addiction, and substance use disorder is present across income groups. At a population level, insecure housing, unemployment, stigma, violence, criminal justice contact, and treatment barriers can combine to increase vulnerability and hinder recovery. These processes are potentially bidirectional: substance-related impairment can worsen employment and housing, while unemployment and housing instability may increase risk. A scoping review of 50 longitudinal studies documented these links while identifying substantial gaps in research on upstream determinants and overdose outcomes. Lin et al., 2024.

Clinical histories should therefore ask about material safety and resources when relevant, including stable accommodation, accessible transportation, insurance, childcare, food, protection from violence, and the ability to obtain ongoing care. These are relevant determinants of what help is feasible. Epidemiologic associations between a neighborhood characteristic and an outcome cannot establish the circumstances or motives of any single resident.

Psychological Mechanisms That Link Risk Factors to Use

Reinforcement and learning

Psychoactive substances can produce immediate changes in experience, which are learned in relation to the contexts that accompany use. Positive reinforcement refers to the increased likelihood of a behavior following a rewarding consequence. Negative reinforcement refers to increased behavior because an unpleasant state is relieved. Alcohol used to reduce social tension, opioids used to suppress withdrawal symptoms, and stimulants associated with energy or social confidence illustrate different learning opportunities. The subjective function of use may change over time, and relief in the short term can coexist with longer-term harm. These processes help connect exposure to repeated behavior without making every form of use pathological.

As repeated associations accumulate, environmental cues, memories, and expectations may elicit urges or guide habits. Stress and sleep disturbance can affect the ability to pause and choose among responses. Neurobiology includes dopamine-related learning, incentive motivation, stress systems, and control networks, but no single neurotransmitter or brain area serves as a complete explanation of addiction. The mechanism-focused account belongs to the separate brain-and-addiction topic; this article explains why different people encounter and respond to those mechanisms under different conditions. NIDA, The Science of Addiction.

Temperament, mental health, and self-regulation

Traits involving impulsivity, sensation seeking, disinhibition, or a tendency toward negative affect can be associated with patterns of substance use, but trait measures do not diagnose substance use disorder. Psychological characteristics overlap with developmental stage, environment, and heritable factors. A person might use a drug for novelty, belonging, relief, sleep, or relief of withdrawal; reasons can coexist and shift. Distress can precede use, result from use, or arise from a shared background factor. Apparent self-medication therefore requires individual assessment rather than a single causal narrative.

Anxiety, depression, trauma-related symptoms, attention difficulties, and other psychiatric conditions are clinically relevant because they can change substance exposure, motivations, treatment needs, and outcomes. Substance use itself can precipitate or worsen symptoms. A careful assessment considers timing, substance effects, withdrawal, and independent mental health conditions. The related articles Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity and Neuroticism and Addiction: Substance Use, Negative Affect, and Risk own those more specific clinical and personality questions.

Trauma and stress responses

Severe stress and trauma can be associated with increased vulnerability through emotional distress, altered expectations of safety, social disruption, and use of substances for relief. The mechanisms are heterogeneous; trauma histories are neither necessary nor sufficient for addiction. Stress can also influence use among people with established disorders and during recovery, but the causes of initial disorder and causes of recurrence after treatment are distinct questions. For clinical care, a trauma-informed approach prioritizes safety, choice, collaboration, and access to appropriate treatment without requiring a person to disclose traumatic experiences before receiving help. NIDA's research priorities.

How Genetics and Environment Interact

Gene–environment correlation

Genes and environments are statistically connected in several ways. Parents transmit genes while also influencing children's homes and opportunities. A young person's behavioral tendencies can evoke responses from others or shape choices of friends and activities. People with particular predispositions may gravitate toward settings that also change drug exposure. Such gene–environment correlation can make an exposure appear to be an independent external cause when part of the association reflects shared inherited liability. Adoption, siblings, children-of-twins designs, and genetically informed longitudinal studies can help isolate some of these paths, although each method has its own assumptions. Genetic and Environmental Interplay in Adolescent Substance Use Disorders.

Gene–environment interaction

An interaction occurs when the relationship between an exposure and outcome differs by genetic liability, or equivalently when the expression of genetic differences varies across environments. A 2025 observational study of adolescent polysubstance use examined polygenic liability alongside peer victimization, prenatal substance exposure, and availability; it reported interactions for several measured environmental factors. The findings are suggestive and require replication across designs, age groups, ancestry groups, and independently measured outcomes. Statistical interaction depends on the outcome scale, and observational interactions alone do not demonstrate the molecular mechanism. Unravelling Polygenic Risk and Environmental Interactions in Adolescent Polysubstance Use.

A supportive environment can alter trajectories for people with substantial inherited liability. Conversely, pervasive access or severe adversity can elevate risk even for people without a known family history. There is no fixed equation that converts a set of risk factors into an individual forecast. Risk emerges through time-dependent processes involving exposure, development, opportunity, and protection.

Epigenetics: biological plausibility and evidence limits

Epigenetic regulation changes how genes are expressed without changing their underlying DNA sequence. Substance exposure, stress, and development can influence gene expression and molecular regulation. Animal models and cellular studies demonstrate plausible links between repeated exposure, neural plasticity, and addiction-related behavior; translating those mechanisms into validated human risk markers or treatment targets is much more difficult. Human epigenetic associations can reflect prior exposure, medication, smoking, stress, cell composition, and other influences. Claims that a single traumatic experience permanently switches on an addiction gene, or that a clinical intervention reverses a person's inherited addiction risk, go beyond established evidence. NIDA strategic discussion of epigenetics.

Why Causes Differ Across Substances

Alcohol and tobacco

Alcohol and nicotine are widely available in many settings, and their exposure is strongly shaped by legal restrictions, price, retail environments, cultural norms, and patterns of social use. Nicotine's delivery route and reinforcement properties matter, as do biological differences in response and the development of tolerance or withdrawal. Alcohol carries distinct metabolic and physiological features, including severe withdrawal syndromes in some dependent people. A common inherited vulnerability may influence both disorders, while substance-specific genes and environments influence their expression. Hatoum et al., 2023.

Opioids

Opioid use disorder can develop within contexts of prescribed or nonprescribed exposure, pain, trauma, stress, and changing drug supply. The distinction between medically expected physiological dependence during treatment and opioid use disorder depends on impaired control, harms and the clinical pattern, not withdrawal symptoms alone. Opioid overdose is a medical emergency often involving dangerously slow breathing; its probability is affected by drug potency, combined sedatives, and tolerance. Understanding causal pathways does not replace effective treatment. CDC guidance on opioid use disorder care identifies medications as central to treatment, and CDC naloxone guidance addresses overdose reversal.

Cannabis and stimulants

Cannabis use disorder and stimulant use disorders share some general vulnerabilities with other substance disorders, while differing in intoxication patterns, withdrawal features, social access, and medical risks. Frequent cannabis use and early exposure are relevant correlates of risk, but population estimates depend strongly on definitions and samples. Stimulants can produce distinct acute cardiovascular and psychiatric emergencies. Broad causal factors such as impulsivity, distress, and opportunity must therefore be paired with substance-specific pharmacology and medical assessment. Evidence supports addressing both shared vulnerability and drug-specific consequences rather than treating every substance as an interchangeable exposure.

Polysubstance use and combined risks

Many individuals use more than one substance, whether concurrently or at different times. Combined use can reflect availability, shared liability, coping, social context, or established dependence. Interaction effects on acute toxicity require special attention: combining opioids with alcohol or benzodiazepines can dangerously suppress breathing. A risk-factor discussion does not establish a diagnosis or reveal which substance is driving impairment; careful clinical history and assessment are essential.

What Research Can Establish About Causation

Family and twin designs

Family and twin research can estimate genetic and environmental components of variation. Comparisons are informative precisely because relatives differ in genetic similarity and often share circumstances. Nevertheless, equal-environments assumptions, selective participation, changes in diagnostic definitions, and the fact that families transmit both genes and environments constrain causal interpretations. Such research is strongest when triangulated with molecular genetics and longitudinal observations. Meyers and Dick.

Longitudinal cohorts and quasi-experiments

Repeated measurement can establish whether an exposure precedes later substance-related problems and can assess changing environments, confounders, and developmental transitions. Sibling comparisons and natural experiments may reduce certain biases. They cannot account automatically for every unmeasured difference between people, and they may have limited generalizability. Associations involving homelessness, criminal justice contact, or mental illness are especially vulnerable to reciprocal causation: a condition can contribute to later addiction, while addiction can worsen the condition. Lin et al., 2024.

Genomic association and Mendelian randomization

Genome-wide association studies detect variants correlated with measured traits across populations. They can illuminate biological pathways and shared liability, but associations do not by themselves identify a causal gene, tissue, cellular mechanism, or therapeutic target. Mendelian randomization uses genetic variants as instruments to investigate particular causal hypotheses; it relies on assumptions about pleiotropy, population structure, and whether the instruments affect the outcome only through the exposure of interest. Substance-use outcomes are especially sensitive to ascertainment, opportunity for exposure, and diagnostic variation. A convergent result across different research designs is stronger than a dramatic result from one technique.

Randomized prevention trials

Randomized interventions can test whether changing a modifiable factor alters future outcomes. They provide direct evidence for specific programs under specific conditions, not proof that every target factor is a sole cause of addiction. In a systematic evidence review used by the US Preventive Services Task Force, effects of preventive counseling interventions for illicit and nonmedical drug use among youth were inconsistent and imprecise. The Task Force concluded that evidence was insufficient to determine the overall balance of benefits and harms for primary care-based prevention in that population. This conclusion concerns those interventions and that question; it does not mean all community, family, or substance-specific prevention is ineffective. O'Connor et al., 2020; USPSTF recommendation.

A Practical Model of Accumulating Risk and Protection

A useful conceptual model follows several linked questions across time. First, what opportunities for substance exposure are present? Second, how does the individual experience the substance, given biology, mental health, expectations, and context? Third, what repeated rewards or relief maintain use? Fourth, which protective resources, costs, responsibilities, and relationships influence further exposure? Finally, has the pattern developed into clinically significant impairment, and what supports change? These questions are designed to guide assessment; they are not a validated numerical prediction instrument.

For one person, frequent drinking could begin as a socially reinforced practice within an alcohol-centered environment and intensify after a period of loss or insomnia. For another, repeated use may be intertwined with psychiatric symptoms or a disrupted social network. A third person with a strong family history may never use a given drug or may stop use without developing a disorder. Each trajectory can reflect multiple influences without requiring a universal sequence of stages.

Protective resources are dynamic. Stable supportive relationships, accessible health care, education, meaningful work, safe housing, culturally responsive services, and opportunities to develop coping skills can change the probability of exposure and the feasibility of recovery. None guarantees protection. The US Surgeon General's report on addiction organizes protective factors at individual, family, school, and community levels; the NIH also emphasizes social support and environments across the lifespan.

Implications for Screening, Clinical Assessment, and Care

Ask about current harm, not only past risk

Risk factors help shape compassionate inquiry but cannot substitute for diagnosis. Clinical evaluation centers on the actual pattern of use, impaired control, consequences, craving, duration, functional impairment, intoxication, withdrawal, medications, co-occurring symptoms, and patient goals. Screening instruments identify people who may benefit from additional assessment. A positive screen does not establish a diagnosis, and a family history, trauma score, or genetic score is never sufficient by itself. Clinicians should evaluate medical danger independently of diagnostic severity: overdose, severe withdrawal, and acute intoxication can require immediate care.

Treatment targets mechanisms and present needs

Once a substance use disorder exists, addressing its causes can inform treatment choices, but proven treatment should not be delayed while searching for a definitive origin story. Medication treatment for opioid use disorder, indicated medications for alcohol use disorder, effective tobacco cessation care, and behavioral interventions can be selected based on the substance and person. Withdrawal management can address acute physiological instability, while ongoing care addresses the enduring disorder, psychiatric comorbidity, relationships, and health. CDC, Opioid Use Disorder: Treating; NIDA, Treatment and Recovery.

People at risk of alcohol or benzodiazepine withdrawal may need medically supervised assessment because abrupt cessation can lead to severe complications, including seizures or delirium. Opioid overdose signs such as inability to awaken and slow or absent breathing require immediate emergency services; administer naloxone if available while obtaining urgent help. Sudden severe chest pain, severe agitation, seizure, hyperthermia, or altered consciousness following stimulant use also require emergency evaluation. A clinical risk factor never justifies a home detoxification regimen or an unsupervised medication change. ASAM alcohol withdrawal guideline; ASAM benzodiazepine tapering guideline; CDC naloxone guidance.

Prevention must match the setting and evidence

For families and educators, protective practice includes responsive relationships, age-appropriate supervision, accurate information, safe opportunities for social involvement, attention to school difficulties, and timely access to mental health and substance-related care. Population responses consider availability, safer prescribing, treatment access, stigma, housing, and local exposure patterns. Programs should be evaluated on actual clinical or behavioral outcomes, possible harms, uptake, and equity; descriptive correlations cannot by themselves establish prevention effectiveness. The NIDA prevention principles recommend matching interventions to developmental stage, community needs, and modifiable factors.

Individual risk is changeable, and recovery has several pathways

People with a high-risk background can develop lasting recovery, and people without a striking history of risk may develop a disorder requiring care. Clinical improvement can involve sustained abstinence, meaningful reduction of harmful consumption where clinically appropriate, remission, improved function, or a combination of outcomes. Recurrence of use calls for reassessment and renewed access to support, not retrospective claims that the person was genetically destined to fail. The goals and medically appropriate care vary by substance and individual circumstances. Causation research is most useful when it strengthens prevention, makes treatment accessible, and identifies changeable conditions.

Common Questions About the Causes of Addiction

Is addiction hereditary?

There is a substantial inherited contribution to population differences in substance use disorders, commonly estimated around 40–60% in many twin-study contexts. Inheritance involves many small genetic effects, not a single addiction gene. Environmental exposure, development, support, and care influence whether vulnerability is expressed. A family history raises concern without predicting an individual's future. NIH.

Can childhood trauma cause addiction?

Childhood trauma is associated with elevated risk in longitudinal research and may contribute through stress, coping, relationships, and exposure opportunities. The strength and causal meaning of associations vary by study design and measured substance outcome. Many trauma survivors do not develop addiction, and many people with addiction report no such history. Trauma-informed care addresses relevant needs without assuming a single cause. Systematic review of childhood adversity and later cannabis outcomes.

Does starting substance use young cause later addiction?

Early initiation is an important predictor, but the association mixes possible effects of extended exposure with preexisting family, genetic, social, and behavioral risks. It is a meaningful prevention target, particularly because young people can face acute harms and developing systems of self-regulation. Predictive association and independent causal effect should be distinguished. NIH youth substance-use overview.

Does an addictive personality exist?

There is no single personality profile that diagnoses or explains all substance use disorders. Traits such as impulsivity and negative emotionality can correlate with risk, while behavior depends on pharmacology, context, learning, access, stress, and individual history. Diagnostic assessment evaluates clinically significant use-related impairment and symptoms. For the separate personality question, see Neuroticism and Addiction.

Can genetic tests tell whether someone will become addicted?

Current genetic findings are informative for research but do not provide a validated yes-or-no clinical test for future addiction. Polygenic scores have limitations involving prediction, population ancestry, environmental confounding, and communication of uncertainty. Clinical assessment and modifiable circumstances remain central. Clinical review of polygenic scores.

Does stress explain every relapse?

Stress can increase risk of use or recurrence for some individuals, but recurrence has multiple determinants including cues, withdrawal, social networks, treatment access, psychiatric symptoms, and changes in support. A person may experience stress without returning to use and may return to use without an identifiable stressful event. The mechanisms and care strategies should be evaluated on an individual basis.

Can a person develop addiction without trauma or a family history?

Yes. Family history and trauma are risk factors, not diagnostic requirements. Exposure, drug effects, repeated reinforcement, availability, other mental health conditions, and changes in life circumstances can interact in ways that lead to a disorder. A clinical diagnosis depends on the pattern of symptoms and impairment, regardless of which risks are present.

Related Articles

Cluster Substance Use Disorders and Addiction Recovery — the central scientific chapter on substance use disorders, diagnosis, treatment, and recovery.

Neuroticism and Addiction: Substance Use, Negative Affect, and Risk — the distinct personality and negative-affect research question.

Growing Up With Parental Substance Use: Childhood Adversity and Adult Outcomes — developmental and family consequences of parental substance exposure.

Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — co-occurring anxiety, coping motivations, and clinical differentiation.

How Addiction Affects the Brain: Reward, Learning, and Control — reward learning, salience, motivation, and control in addiction neuroscience.

Stress and Addiction: Coping, Negative Reinforcement, and Relapse — stress systems, coping behavior, negative reinforcement, and recurrence of use.

Teen Substance Use Disorders: Warning Signs, Assessment, and Care — adolescent patterns, age-appropriate screening, family-based care, and safeguards.

References

American Society of Addiction Medicine. (2020). Clinical practice guideline on alcohol withdrawal management. Official guideline.

American Society of Addiction Medicine and partner societies. (2025). Joint clinical practice guideline on benzodiazepine tapering. Official guideline.

Centers for Disease Control and Prevention. (2024). Five things to know about naloxone. Official guidance.

Centers for Disease Control and Prevention. (2024). Opioid use disorder: Treating. Official clinical guidance.

Hatoum, A. S., et al. (2023). Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders. Nature Mental Health, 1, 210–223. https://doi.org/10.1038/s44220-023-00034-y.

Kember, R. L., Davis, C. N., Feuer, K. L., and Kranzler, H. R. (2024). Considerations for the application of polygenic scores to clinical care of individuals with substance use disorders. Journal of Clinical Investigation, 134(20), e172882. https://doi.org/10.1172/JCI172882.

Lin, C., Cousins, S. J., Zhu, Y., et al. (2024). A scoping review of social determinants of health's impact on substance use disorders over the life course. Journal of Substance Use and Addiction Treatment, 166, 209484. https://doi.org/10.1016/j.josat.2024.209484.

Meyers, J. L., and Dick, D. M. (2010). Genetic and environmental risk factors for adolescent-onset substance use disorders. Child and Adolescent Psychiatric Clinics of North America, 19(3), 465–477. https://doi.org/10.1016/j.chc.2010.03.013.

National Institute on Drug Abuse. (2016). Strategic plan 2016–2020: Epigenetics and addiction. Official report.

National Institute on Drug Abuse. (n.d.). Drugs, brains, and behavior: The science of addiction. Official research resource.

National Institute on Drug Abuse. (n.d.). Preventing drug use among children and adolescents: Principles of prevention. Official publication.

National Institute on Drug Abuse. (n.d.). Treatment and recovery. Official resource.

National Institutes of Health. (n.d.). Substance use disorders. NIH Health.

National Institutes of Health. (n.d.). Youth and young adult alcohol and other substance use. NIH Health.

O'Connor, E., Thomas, R., Robalino, S., et al. (2020). Interventions to prevent illicit and nonmedical drug use in children, adolescents, and young adults: Updated systematic evidence review. Agency for Healthcare Research and Quality. NCBI Bookshelf.

Rhee, S. H., et al. (2003). Genetic and environmental influences on substance initiation, use, and problem use in adolescents. PubMed.

United States Preventive Services Task Force. (2020). Illicit drug use in children, adolescents, and young adults: Primary care-based interventions. Recommendation statement.